BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 37804819)

  • 1. Xie Zhuo Tiao Zhi formula modulates intestinal microbiota and liver purine metabolism to suppress hepatic steatosis and pyroptosis in NAFLD therapy.
    Qiu J; Chen L; Zhang L; Xu F; Zhang C; Ren G; Chang K; He G; Du Z; Le Y; Yu Z; Li S; Liu Q; Dou X
    Phytomedicine; 2023 Dec; 121():155111. PubMed ID: 37804819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xiezhuo Tiaozhi formula inhibits macrophage pyroptosis in the non-alcoholic fatty liver disease by targeting the SIRT1 pathway.
    Tian L; Chen J; Yang M; Chen L; Qiu J; Jiang Y; Tan X; Qian Q; Liang X; Dou X
    Phytomedicine; 2024 May; 131():155776. PubMed ID: 38851104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota.
    Han R; Qiu H; Zhong J; Zheng N; Li B; Hong Y; Ma J; Wu G; Chen L; Sheng L; Li H
    Phytomedicine; 2021 May; 85():153544. PubMed ID: 33773192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ling-Gui-Zhu-Gan decoction ameliorates nonalcoholic fatty liver disease via modulating the gut microbiota.
    Chen L-p; Zhang L-f; Liu S; Hua H; Zhang L; Liu B-c; Wang R-r
    Microbiol Spectr; 2024 Jun; 12(6):e0197923. PubMed ID: 38647315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Xiaozhi formula attenuates non-alcoholic fatty liver disease by regulating lipid metabolism via activation of AMPK and PPAR pathways.
    You L; Wang T; Li W; Zhang J; Zheng C; Zheng Y; Li S; Shang Z; Lin J; Wang F; Qian Y; Zhou Z; Kong X; Gao Y; Sun X
    J Ethnopharmacol; 2024 Jul; 329():118165. PubMed ID: 38588984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease.
    Wang W; Zhao J; Gui W; Sun D; Dai H; Xiao L; Chu H; Du F; Zhu Q; Schnabl B; Huang K; Yang L; Hou X
    Br J Pharmacol; 2018 Feb; 175(3):469-484. PubMed ID: 29139555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erchen Decoction alleviates obesity-related hepatic steatosis via modulating gut microbiota-drived butyric acid contents and promoting fatty acid β-oxidation.
    Zhang L; Chen N; Zhan L; Bi T; Zhou W; Zhang L; Zhu L
    J Ethnopharmacol; 2023 Dec; 317():116811. PubMed ID: 37336336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Traditional Chinese Medicine formula Dai-Zong-Fang alleviating hepatic steatosis in
    Zhang LW; Zhu LL; Zhu XY; Fu SQ; Liu XM
    Front Pharmacol; 2024; 15():1337057. PubMed ID: 38327989
    [No Abstract]   [Full Text] [Related]  

  • 10. Lingguizhugan decoction improves non-alcoholic steatohepatitis partially by modulating gut microbiota and correlated metabolites.
    Zhu M; Wang X; Wang K; Zhao Z; Dang Y; Ji G; Li F; Zhou W
    Front Cell Infect Microbiol; 2023; 13():1066053. PubMed ID: 36779187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Zhishi Daozhi Decoction on the intestinal flora of nonalcoholic fatty liver disease mice induced by a high-fat diet.
    Bi CR; Sun JT; Du J; Chu LY; Li YJ; Jia XY; Liu Y; Zhang WP; Li YC; Liu YJ
    Front Cell Infect Microbiol; 2022; 12():1005318. PubMed ID: 36683694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
    Lee MR; Yang HJ; Park KI; Ma JY
    Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Penthorum chinense Pursh. extract attenuates non-alcholic fatty liver disease by regulating gut microbiota and bile acid metabolism in mice.
    Li X; Zhao W; Xiao M; Yu L; Chen Q; Hu X; Zhao Y; Xiong L; Chen X; Wang X; Ba Y; Guo Q; Wu X
    J Ethnopharmacol; 2022 Aug; 294():115333. PubMed ID: 35500802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysregulated hepatic lipid metabolism and gut microbiota associated with early-stage NAFLD in ASPP2-deficiency mice.
    Xie F; Xu HF; Zhang J; Liu XN; Kou BX; Cai MY; Wu J; Dong JL; Meng QH; Wang Y; Chen D; Zhang Y
    Front Immunol; 2022; 13():974872. PubMed ID: 36466835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of bioactive components and synergistic action mechanism of ShuGan-QieZhi Capsule for treating non-alcoholic fatty liver disease.
    Zhu T; Huang X; Zhu H; Chen J; Yao H; Zhang Y; Hua H; Zhang J; Qi J
    Phytomedicine; 2024 Jan; 123():155173. PubMed ID: 37976695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Astragalus mongholicus polysaccharides ameliorate hepatic lipid accumulation and inflammation as well as modulate gut microbiota in NAFLD rats.
    Zhong M; Yan Y; Yuan H; A R; Xu G; Cai F; Yang Y; Wang Y; Zhang W
    Food Funct; 2022 Jul; 13(13):7287-7301. PubMed ID: 35726797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Network pharmacology-based investigation to explore the effect and mechanism of Erchen decoction against the nonalcoholic fatty liver disease.
    Liu H; Xu J; Li H; Zhang L; Xu P
    Anat Rec (Hoboken); 2021 Nov; 304(11):2605-2619. PubMed ID: 34536264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atractylenolide III ameliorates Non-Alcoholic Fatty Liver Disease by activating Hepatic Adiponectin Receptor 1-Mediated AMPK Pathway.
    Li Q; Tan JX; He Y; Bai F; Li SW; Hou YW; Ji LS; Gao YT; Zhang X; Zhou ZH; Yu Z; Fang M; Gao YQ; Li M
    Int J Biol Sci; 2022; 18(4):1594-1611. PubMed ID: 35280674
    [No Abstract]   [Full Text] [Related]  

  • 19.
    Li H; Wang XK; Tang M; Lei L; Li JR; Sun H; Jiang J; Dong B; Li HY; Jiang JD; Peng ZG
    Gut Microbes; 2024; 16(1):2304159. PubMed ID: 38277137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium butyrate ameliorates non-alcoholic fatty liver disease by upregulating miR-150 to suppress CXCR4 expression.
    Zhang N; Qu Y; Qin B
    Clin Exp Pharmacol Physiol; 2021 Aug; 48(8):1125-1136. PubMed ID: 33721354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.